Lund Arthritis Research Group (LARG)
41 – 50 of 119
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Belonging, happiness, freedom and empowerment-a qualitative study of patients' understanding of health in early rheumatoid arthritis
- Contribution to journal › Article
- 2023
-
Mark
Elevated fecal levels of the inflammatory biomarker calprotectin in early systemic sclerosis
- Contribution to journal › Article
-
Mark
Validity of clinical psoriatic arthritis diagnoses made by rheumatologists in the Swedish National Patient Register
- Contribution to journal › Article
-
Mark
The effect of a tight control regime with monthly follow-up on remission rates and reported pain in early rheumatoid arthritis
- Contribution to journal › Article
-
Mark
How good is the agreement between clinical diagnoses and classification criteria fulfilment in axial spondyloarthritis? Results from the SPARTAKUS cohort
- Contribution to journal › Article
-
Mark
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: Data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
- Contribution to journal › Article
-
Mark
Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis : A Decision Tree Analysis by Indication
- Contribution to journal › Article
-
Mark
Healthcare professionals' perceptions of working on lifestyle management for patients with early rheumatoid arthritis - a qualitative study
(2023) In International Journal of Qualitative Studies on Health and Well-being 18(1). p.2241225-2241225
- Contribution to journal › Article
-
Mark
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
- Contribution to journal › Scientific review
-
Mark
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis : 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial
- Contribution to journal › Article
